Please select the option that best describes you:
Topics:
Genitourinary Cancers • Medical Oncology
In light of the recent results from STAMPEDE and LATITUDE, to which patients with newly diagnosed metastatic prostate cancer are you offering up-front abiraterone vs. up-front docetaxel?
Pending head-to-head comparisons, do you believe there are any subgroups who might benefit more from one or the other?
Answer from: Medical Oncologist at Academic Institution
Although I anticipate that the Stampede investigators will publish (an underpowered) comparison of their ADT plus docetaxel arm vs ADT plus abiraterone which may provide some insight, for the most part we will be in a data free zone re: this issue for some time. I suspect that clinicians will ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
The high volume patients who were getting chemo will be offered abiraterone provided the cost of the drug will be covered. I will hold off on the low volume patients for now- the median rPFS for the low volume patients on ADT alone on the GETUG 15 was 21 months. I would also not treat M0 patients . ...